アイオワ州における過体重の臨床試験
アイオワ州内の拠点で、過体重に関する9件の研究が参加者を募集しています。
アイオワ州内の都市
公式研究テキスト（英語）
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Iowa Diabetes and Endocrinology Research Center, West Des Moines
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07794579A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Iowa Diabetes and Endocrinology Research Center, West Des Moines
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07392190Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- McFarland Clinic PC, Ames
- Midwest Cardiovascular Research Foundation, Davenport
被験者募集中第3相
45歳〜99歳 · 全性別 · 2026/09/22更新 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Iowa Diabetes and Endocrinology Research Center, West Des Moines
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07321886A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Des Moines
- ACCOMPLISH-2 Research Site, Iowa City
被験者募集中第3相健康なボランティア歓迎
18歳〜79歳 · 全性別 · 2026/09/11更新 · NCT07654374A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Iowa Diabetes and Endocrinology Research Center, West Des Moines
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/08更新 · NCT06143956Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- Iowa Diabetes Research, West Des Moines
被験者募集中第3相
18歳〜99歳 · 全性別 · 2026/09/03更新 · NCT07684144A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Ames
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/25更新 · NCT07784725Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Iowa City
被験者募集中第3相
18歳〜79歳 · 全性別 · 2026/08/10更新 · NCT07654361ClinicalTrials.govより、2026/10/03時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。